Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Sixty-seven adult walleye fish were examined by light and transmission electron microscopy. The fish were affected by a mesenchymal tumor previously termed Walleye Dermal Sarcoma that commonly affects up to 27% of the population seasonally. Biopsies from 24 fish were collected, and complete postmortem examinations were performed on 43 fish. Grossly, the tumors had the appearance of randomly distributed, often clustered, spherical nodules, 2-5 mm in diameter with a smooth and often ulcerated surface. The tumors arose from the superficial surface of scales and consisted of fibroblast-like cells separated by a moderate amount of collagen (43/67) or osteoid material (24/67). Lymphocytic infiltration (28/67) associated with vacuolar degeneration of tumor cells (28/67) and centrally located coagulation necrosis (30/67) were observed. Although tumor cells were often highly anaplastic, no local invasions or metastases were present. In contrast with previous descriptions of this tumor, no viral particles could be observed electron microscopically. The variably anaplastic appearance of the tumor, its biological behavior, and its restriction to dermis are features in common with canine cutaneous histiocytoma and equine sarcoid. The multicentric origin, the restriction to the dermis, and the absence of invasion or metastases of Walleye Dermal Sarcoma differ from retrovirus-induced avian and murine sarcomas that arise locally, that invade, and that often metastasize.
 ...
PMID:Histologic and ultrastructural studies of dermal sarcoma of walleye (Pisces: Stizostedion vitreum). 223 87

Sarcoma of the breast represents less than 1% of primary mammary malignancies; this study reports 25 such cases. The largest group had malignant fibrous histiocytoma (44%), followed by liposarcoma (24%) and fibrosarcoma (16%). Also represented were clear cell sarcoma, neurogenic sarcoma, leiomyosarcoma, and alveolar soft part sarcoma (4% each). Of 19 patients treated by wide local excision or simple mastectomy with or without adjuvant radiotherapy, 11 had local recurrence develop, of which one patient died and nine of the remaining ten had metastases develop. Of the remaining eight patients in this group with no local recurrence, only two had metastases develop. Of the six patients treated by radical or Patey mastectomy, none had local recurrence develop, but two died of metastases. No patient had metastases develop more than 5 years after diagnosis. Regional lymph node involvement with tumor was observed in only one patient (with malignant fibrous histiocytoma) despite regional lymphadenopathy in seven. The overall mortality at 5 years is 64% but does not increase thereafter. The authors' findings suggest that failure to establish local control is associated with a poor prognosis and that wide local excision or simple mastectomy does not provide sufficient clearance to be used as first-line treatment. Excision of the axillary lymphatics and adjuvant radiotherapy are unlikely to be beneficial.
 ...
PMID:Breast sarcoma. A clinicopathologic review of 25 cases. 238 20

The behavior of two spontaneous transplantable rat tumors and a mouse lymphoma was studied in different hosts. A resistant (eR) subline to Sarcoma E 100 (S-E 100) and a susceptible one (eS) were obtained by divergent selection carried out in an inbred line of rats IIM (e). The phenotypic frequencies of the resistant and susceptible individuals to S-E 100 in the base population e and eR, eS, F1 and F2 fitted with the theoretical frequencies of a model of two independent pairs of genes, one (T) with complete dominance (locus SE1) and the other (R) with partial dominance (locus SE2). Locus SE2 would regulate the antitumoral response. Resistance to S-E 100 was found to be a dominant trait. The subcutaneous challenge of eR and eS rats with Lymphoma TACB (L-TACB) showed a different behavior. Subline eR (resistant to S-E 100) was susceptible to L-TACB while subline eS (susceptible to S-E 100) was resistant. A tumor-host interaction was found, revealing that genotypes resistant to S-E 100 were susceptible to L-TACB; in addition, susceptible animals (eR) developed lymph node metastases. It was observed, using animals of different genotypes, that susceptibility to L-TACB metastases and to local tumor growth, would be conditioned by different genes. Delayed type hypersensitivity (DTH) to tumor antigens (S-E 100 and L-TACB) and humoral immune response and DTH to sheep red blood cells (SRBC) were investigated in eR and eS rats. Differences between both sublines were statistically significant suggesting that genes involved in the divergent selection would regulate the antitumoral immune response.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:[Inheritance of susceptibility to tumors and metastases in rodents]. 248 19

From 1981 to 1986, 240 patients with primary, malignancy grade III or IV soft-tissue sarcoma were entered into a randomized adjuvant chemotherapy multicenter trial, conducted by the Scandinavian Sarcoma Group. After a median follow-up time of 46 (2-97) months, a multivariate analysis of risk factors for metastases was performed in 138 radically operated on patients with tumors of the extremities. Adjuvant single-agent doxorubicin did not improve the metastasis-free survival. Histologic malignancy grade IV, tumor size greater than 10 cm, vascular invasion by tumor, and male sex were identified as risk factors. Patients with no or one risk factor had a 5-year metastasis-free survival of 0.7, with two risk factors 0.5, and with three or four risk factors 0.2. The combination of different risk factors provides a prognostic model for soft tissue sarcomas, which could be a basis for therapeutic trials.
 ...
PMID:Prognosis in high-grade soft tissue sarcomas. The Scandinavian Sarcoma Group experience in a randomized adjuvant chemotherapy trial. 269 May 57

Soft-tissue sarcomas account for only 1% of all malignant lesions. The Canadian Sarcoma Group encourages the investigation and management of these tumours at tertiary institutions, where a multidisciplinary team can handle the complex problems. Staging of these tumours implies accurate anatomic determination of the extent of disease, the histogenesis and grade of the tumours and the presence of regional or distant metastases. Arteriography, computed tomography and magnetic resonance imaging can accurately define the tumour before biopsy. The biopsy should be muscle-splitting to minimize contamination of additional compartments and should allow inclusion of the biopsy site at definitive surgical resection. It should be done at the institution where definitive management will be performed. Regional lymph-node involvement can be detected using magnetic resonance imaging or gallium scanning, whereas for distant metastases, specifically of lung, computed tomography is the method of choice. To date no one staging system for soft-tissue sarcomas has been universally accepted. A hybrid, encompassing the advantages of each system, is being formulated.
 ...
PMID:Incidence, investigations and staging of soft-tissue sarcoma. 317 47

Previous studies have indicated the efficacy of adoptive immunotherapy utilizing recombinant interleukin-2 (rIL-2) and lymphokine-activated killer (LAK) cells in the treatment of advanced neoplastic disease. However, this therapeutic approach is associated with considerable toxicity, primarily due to the systemic administration of rIL-2. The present study was undertaken to determine the efficacy of a newly developed water-soluble glucan, when administered in combination with LAK cells, in the therapy of experimental hepatic metastases. Mice were challenged subcutaneously (1 X 10(4) cells) with reticulum cell sarcoma M5076 on day 0. Therapy was initiated on day 15, when a palpable primary tumor mass and hepatic micrometastases were evident, and continued at 3-day intervals up to day 54. Sarcoma-bearing mice received glucan (250 mg/kg) intravenously, either alone or in combination with LAK cells (1 X 10(7)/mouse). Control mice received 5% (wt/vol) dextrose in water. Glucan-LAK cell therapy significantly suppressed primary tumor growth, inhibited the progression of hepatic metastases and prolonged survival in sarcoma-bearing mice. Splenocytes, incubated with rIL-2 for 72 h, exhibited significant natural killer (NK) cell activity and were cytotoxic to sarcoma cells in vitro. Glucan-LAK cell administration resulted in significant increases in splenic NK cell activity and Kupffer cell-mediated tumoricidal activity. In addition, bone marrow proliferation was enhanced following the co-administration of glucan and LAK cells. Due to its nontoxic nature and immunostimulating properties, soluble glucan may prove to be an attractive biological response modifying agent for utilization in adoptive immunotherapy of advanced neoplastic disease.
 ...
PMID:Soluble glucan and lymphokine-activated killer (LAK) cells in the therapy of experimental hepatic metastases. 328 99

Soft tissue sarcomas are uncommon malignancies, less than 10% of which arise on the distal upper extremities. Consequently, experience with treatments which preserve both the limb and its function is lacking for tumors in this region. Sixteen patients with sarcomas arising in the hand and wrist and one with an aggressive desmoid tumor were treated by combined modality therapy at the Massachusetts General Hospital. Two patients had wide resections for multiple recurrent lesions, 5 had excisional biopsies, and 9 had incomplete excisions to preserve anatomic structures of the hand. One patient refused an amputation and had no surgery. Sarcoma patients were given postoperative radiation with a dose range of 50.2 to 69 Gy (median 68 Gy). The desmoid tumor received 44 Gy. A shrinking field technique with customized castings and cerrobend blocks was used to assure precision and minimize treatment volumes. Chemotherapy was reserved for metastatic disease. Local control was achieved in 14 patients who received combined modality treatment (87%), with a follow-up 1-12 years (median 33 months). Two of the three patients with local failures subsequently obtained a local control after salvage surgery and radiation. Four patients developed metastases, one with epitrochlear lymph node metastases was salvaged by amputation, the others died with lung disease 17, 37, and 111 months after treatment. Functional integrity of the limb was primarily dependent on the extent of surgical resection required. Among 12 patients with local and distant control, one patient (who had multiple wide resections of an extensive desmoid tumor preceding irradiation) lost over 50% use of her limb, but no patients required amputation for edema or pain control. Ten of the 12 patients with local and distant control had less than a 25% decrement in limb function and had no pain or edema associated with normal use of their hand. We conclude that for selected patients with sarcomas of the distal upper extremity, combined modality therapy consisting of conservative resection and careful radiation therapy is a viable alternative to amputation.
 ...
PMID:Extremity preservation by combined modality treatment of sarcomas of the hand and wrist. 377 12

Glucan, a particulate beta-1,3-polyglucose immunomodulator, was evaluated for its ability to modify hepatic metastases and survival in mice with reticulum cell sarcoma. Sarcoma M5076 cells were injected subcutaneously (1 X 10(5) cells) into syngeneic C57BL/6J male mice. On Day 20, histopathological studies indicated the presence of hepatic micrometastases. At this time, glucan (0.45 mg per mouse) or dextrose was administered intravenously. Therapy was continued at 3-day intervals up to Day 50. By Day 36 postchallenge, the glucan-treated group, when compared to the control group, showed a marked decrease in hepatic metastases, both grossly and histopathologically. A significant inhibition in the growth of the primary tumor also occurred. Plasma clearance of bromosulfophthalein measured on Day 36, denoted that glucan therapy maintained hepatic parenchymal cell functional integrity, while a 4-fold impairment in bromosulfopthalein removal was observed in control mice. Glucan-treated mice showed a 28% (p less than 0.05) long-term survival. In contrast, control mice showed a 100% mortality by Day 42 postchallenge. Studies to evaluate the mechanism of the anti-metastatic action of glucan indicated that 8 days after glucan administration, isolated hepatic macrophages were significantly more cytotoxic to sarcoma cells in vitro than were normal Kupffer cells. At this time, the cytotoxic activity of peritoneal and splenic macrophages from glucan-treated mice were unaltered. Additionally, co-incubation of particulate glucan with diverse populations of normal or tumor cells in vitro indicated that glucan exerted a direct cytostatic effect on sarcoma and melanoma cells and, in contrast, had a proliferative effect on normal spleen and bone marrow cells.(ABSTRACT TRUNCATED AT 250 WORDS)
 ...
PMID:Therapeutic efficacy of glucan in a murine model of hepatic metastatic disease. 388 76

Effects of lysozyme(LY) alone and combination with various antitumor agents were examined using syngeneic tumors mainly Meth-A and MH 134 transplanted into Balb/c and C3H/He mice, respectively. The effects of LY on pulmonary metastases were also examined in BDF1 mice bearing Lewis lung carcinoma (3LL). LY inhibited the growth of Meth-A tumor and enhanced antitumor effects of mitomycin C (MMC). bleomycin (BLM) and 5-fluorouracil (5-FU), LY activated antitumor effects of MMC, BLM and 5-FU on MH 134 tumor, however, LY alone did not show any significant antitumor effect on it. The combination treatments using LY with MMC or 5-FU showed a marked inhibition on pulmonary metastases of 3LL. The pre-treatment of LY inhibited the tumor growth of Sarcoma-180 in ICR mice.
 ...
PMID:[Experimental studies on antitumor effects of lysozyme]. 718 34

A total of 33 patients (median age, 44 years) with high-grade, adult soft-tissue sarcoma were treated with etoposide given at 600 mg/m2 in a 72-h continuous infusion and ifosfamide given at 1500 mg/m2 per day for 3 days every 3 weeks. Dose escalation/reduction was protocolled depending on the level of hematological toxicity observed in the preceding course. Overall, 90% of patients had metastatic disease, and the most common histologies were malignant fibrous histiocytoma and leiomyosarcoma. A median of 5 (range, 1-9) courses were given. Of 30 patients who were evaluable for response, 12 (40%) obtained a partial remission, and the median time to progression was 8 (range, 4-13) months. Grade 3-4 leukopenia and thrombocytopenia were seen after 89% and 8% of the courses, respectively; neutropenic fever was seen in half of the patients (15% of courses); and 32% of courses had to be postponed by 7 days or more due to myelosuppression. Dose reduction to below the standard had to be performed in 46% of courses, and dose escalation was achieved in only 13%. The reduced toxicity seen after the addition of granulocyte colony-stimulating factor (G-CSF) in five patients indicates that growth-factor support may enhance the dose intensity of the regimen. The results indicate significant activity for this regimen in adult soft-tissue sarcoma, which may in part be a result of the escalated dose and prolonged mode of administration of the phase-specific agent etoposide. As a result of this pilot series, a phase II study with ifosfamide, etoposide, and G-CSF in advanced adult soft-tissue sarcoma has been initiated by the Scandinavian Sarcoma Group.
 ...
PMID:Treatment of advanced, high-grade soft-tissue sarcoma with ifosfamide and continuous-infusion etoposide. 753 39


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>